IDYA
Price
$21.92
Change
+$0.80 (+3.79%)
Updated
Jul 2 closing price
Capitalization
1.85B
40 days until earnings call
MRUS
Price
$53.33
Change
+$0.67 (+1.27%)
Updated
Jul 2 closing price
Capitalization
3.92B
28 days until earnings call
Interact to see
Advertisement

IDYA vs MRUS

Header iconIDYA vs MRUS Comparison
Open Charts IDYA vs MRUSBanner chart's image
IDEAYA Biosciences
Price$21.92
Change+$0.80 (+3.79%)
Volume$1.01M
Capitalization1.85B
Merus
Price$53.33
Change+$0.67 (+1.27%)
Volume$589.92K
Capitalization3.92B
IDYA vs MRUS Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. MRUS commentary
Jul 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and MRUS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 03, 2025
Stock price -- (IDYA: $21.92 vs. MRUS: $53.33)
Brand notoriety: IDYA and MRUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 80% vs. MRUS: 42%
Market capitalization -- IDYA: $1.85B vs. MRUS: $3.92B
IDYA [@Biotechnology] is valued at $1.85B. MRUS’s [@Biotechnology] market capitalization is $3.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $306.14B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileMRUS’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • MRUS’s FA Score: 1 green, 4 red.
According to our system of comparison, MRUS is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while MRUS’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 3 bearish.
  • MRUS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both IDYA and MRUS are a good buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а -0.41% price change this week, while MRUS (@Biotechnology) price change was -1.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +33.16%, and the average quarterly price growth was +1.56%.

Reported Earning Dates

IDYA is expected to report earnings on Aug 12, 2025.

MRUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+1.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRUS($3.92B) has a higher market cap than IDYA($1.85B). MRUS YTD gains are higher at: 26.825 vs. IDYA (-14.708). MRUS has higher annual earnings (EBITDA): -298.55M vs. IDYA (-356.46M). IDYA has more cash in the bank: 693M vs. MRUS (458M). MRUS has less debt than IDYA: MRUS (9.86M) vs IDYA (26M). MRUS has higher revenues than IDYA: MRUS (54.7M) vs IDYA (7M).
IDYAMRUSIDYA / MRUS
Capitalization1.85B3.92B47%
EBITDA-356.46M-298.55M119%
Gain YTD-14.70826.825-55%
P/E RatioN/AN/A-
Revenue7M54.7M13%
Total Cash693M458M151%
Total Debt26M9.86M264%
FUNDAMENTALS RATINGS
IDYA vs MRUS: Fundamental Ratings
IDYA
MRUS
OUTLOOK RATING
1..100
6458
VALUATION
overvalued / fair valued / undervalued
1..100
61
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
6627
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
5550
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRUS's Valuation (60) in the Biotechnology industry is in the same range as IDYA (61) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

MRUS's Profit vs Risk Rating (27) in the Biotechnology industry is somewhat better than the same rating for IDYA (66) in the null industry. This means that MRUS’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's SMR Rating (94) in the null industry is in the same range as MRUS (97) in the Biotechnology industry. This means that IDYA’s stock grew similarly to MRUS’s over the last 12 months.

MRUS's Price Growth Rating (50) in the Biotechnology industry is in the same range as IDYA (55) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

MRUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that MRUS’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAMRUS
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
75%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
78%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
77%
Bearish Trend 3 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MRUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMXSX7.90N/A
N/A
Federated Hermes Max-Cap Index Svc
CONWX18.47N/A
N/A
Concorde Wealth Management
FIJFX90.99N/A
N/A
Fidelity Advisor Materials Z
OSCNX21.68N/A
N/A
Invesco Main Street Small Cap R
BAICX10.43-0.01
-0.10%
BlackRock Multi-Asset Income Investor A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with IMNM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+3.79%
IMNM - IDYA
60%
Loosely correlated
+1.95%
CGON - IDYA
60%
Loosely correlated
+1.25%
NRIX - IDYA
58%
Loosely correlated
+6.23%
XENE - IDYA
56%
Loosely correlated
+6.61%
SYRE - IDYA
56%
Loosely correlated
N/A
More

MRUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRUS has been loosely correlated with VIGL. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MRUS jumps, then VIGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRUS
1D Price
Change %
MRUS100%
+1.27%
VIGL - MRUS
49%
Loosely correlated
+0.13%
IDYA - MRUS
49%
Loosely correlated
+3.79%
CGON - MRUS
49%
Loosely correlated
+1.25%
RVMD - MRUS
47%
Loosely correlated
+0.81%
ACLX - MRUS
47%
Loosely correlated
+2.55%
More